Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2)

点击翻译按钮获取中文摘要

In the UK, approximately 4.11 million people have knee osteoarthritis (OA). Consequently 98,147 total knee replacements were performed in 2016 costing £510 million, a rise of 33% in 6 years. Around 10-16,000 people require treatment for cartilage defects every year, which if untreated, can progress to OA. With effective early treatment, OA could be prevented.The National Institute for Clinical Excellence (NICE) have stated that the most cost-effective treatment for cartilage repair is autologous chondrocyte implantation (ACI). ACI is a 2-stage process used to treat cartilage defects in the knee: an initial knee arthroscopy (key-hole surgery) is performed and a cartilage biopsy obtained. The patient's own (autologous) cartilage cells (chondrocytes) are then extracted from the biopsy and grown in the laboratory. The cells are implanted in the cartilage defect at a second surgery ~4 to 6 weeks later. NICE approved ACI in Oct-17, but there has been little adoption by NHS centres due to the regulatory constraints and challenges of an autologous product.Chondrocytes typically do not multiply in the body and when made to do so in the lab can lose their ability to produce cartilage, one potential reason for some ACI failures. However, there is a subpopulation of cells in cartilage called Chondroprogenitors (CPs) which behave more like stem cells and have the ability to be multiplied many times over without affecting their function. We plan to use donated cartilage tissue from organ donors to obtain CPs, which will then be multiplied and implanted into cartilage defects in a single surgery. Consequently, many patients could be treated from a single donor. This could streamline NHS adoption, improve patient access & reduce morbidity in a more cost-effective way compared to standard ACI.Key objectives of the project are:1: Optimise CP manufacture process: Initially we will establish a safe and effective supply of donor cartilage from NHSBT. The current manufacture process will then be optimised and future proofed by removing animal sourced reagents. This will ensure efficient transfer of methodologies to the manufacturing facility (ATF) in Birmingham. Following manufacture, the cells will be frozen and stored. We will then need to determine how long we will be able to store the cells without compromising their function. An initial 6-month shelf life of the cells will be confirmed, with continued tests on-going throughout the project in order to determine the cells' maximum storage time. Quality assurance tests will be finalised to ensure the cells provided are consistent and potent. Prior to transferring protocols to the ATF the manufacture process will be independently reviewed by the Cell and Gene Therapy Catapult so as to ensure there are no apparent flaws in the process that may prevent progression to the clinical trial and future commercialisation.2: The optimised method of cell manufacture from phase 1 of the project will be transferred to the ATF for further confirmatory tests under strict clinical conditions. The licences required from the MHRA and ethical bodies will be obtained in order for us to proceed to the clinical trial.3: A 20 patient trial to investigate allogeneic chondroprogenitors for the treatment of isolated cartilage lesions in the knee will be performed in 3 centres: The Royal Orthopaedic Hospital, Birmingham; The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry and The Nuffield Orthopaedic centre, Oxford. The primary outcome measure will be safety and Patient Reported Outcome Scores, at 3, 6, 9 & 12 months post-operatively. Secondary outcomes will be repair tissue quantity & quality on MRI scans at 12 months.We hope that this project will address a current unmet patient need within the UK and serve as an exemplar for the development of future allogeneic cell therapies.